QCG
PDLI

Quadrant Capital Group’s PDL BioPharma, Inc. PDLI Stock Holding History

Quadrant Capital Group’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-317
Closed -$1K – 2396
2020
Q2 		$1K Hold
317
– – ﹤0.01% 2191
2020
Q1 		$1K Hold
317
– – ﹤0.01% 2087
2019
Q4 		$1K Buy
+317
New +$920 ﹤0.01% 2387
2016
Q3 		– Sell
-222
Closed – – 2172
2016
Q2 		$0 Hold
222
– – ﹤0.01% 2185
2016
Q1 		$0 Sell
222
-577
-72% -$1.8K ﹤0.01% 2188
2015
Q4 		$2K Buy
+799
New +$3.34K ﹤0.01% 1390

Other funds holding PDLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Quadrant Capital Group's PDLI Position: Q3 2020 in Review

Quadrant Capital Group sold out of PDL BioPharma, Inc. (PDLI) in Q3 2020, closing a stake of 317 shares — an estimated $1K sold.

Quadrant Capital Group first reported a position in PDLI in Q4 2015 and held it in 6 quarters. The position peaked at $2K in Q4 2015. 132 funds tracked by Wall St. Rank hold PDLI as of Q3 2020.

  • Quadrant Capital Group reported no remaining PDL BioPharma, Inc. position as of Q3 2020 after selling out during the quarter.
  • Quadrant Capital Group sold 317 PDL BioPharma, Inc. shares in Q3 2020, an estimated $1K.
  • Quadrant Capital Group first reported a position in PDL BioPharma, Inc. in Q4 2015 and held it in 6 quarters.
  • Quadrant Capital Group's PDL BioPharma, Inc. position peaked at $2K in Q4 2015.
  • 132 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2020.

Based on Quadrant Capital Group's 13F filing for Q3 2020, filed 13 Nov 2020.